Biogen Inc. closed 41.53% short of its 52-week high of $238.00, which the company achieved on July 12th.

Biogen (BIIB) announced plans for its new global headquarters at Kendall Common, located at 75 Broadway in Cambridge, as part of a multi-year ...

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics ...

The company and Sanofi just posted positive results from a pivotal ADEPT Phase 2/3 trial. While we’re not seeing any specific news, BIIB has become a value play. Keep your portfolio well-protected ...

Sales of Biogen’s BIIB key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure ...

Commonwealth Equity Services LLC trimmed its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 7.2% in the ...

In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

Today we are looking at Moderna (NASDAQ:MRNA) and the best and worst performers in the therapeutics industry. Over the next few years, therapeutic companies, which develop a wide variety of treatments ...